2012
Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectFemaleHumansMaleMiddle AgedSelf AdministrationSmokingSmoking CessationSubstance Withdrawal SyndromeTobacco Use Cessation DevicesTreatment OutcomeYoung AdultConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational work
1997
Three methods of opioid detoxification in a primary care setting. A randomized trial.
O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals Of Internal Medicine 1997, 127: 526-30. PMID: 9313020, DOI: 10.7326/0003-4819-127-7-199710010-00004.Peer-Reviewed Original ResearchConceptsPrimary care settingOpioid detoxificationCare settingsBuprenorphine groupWithdrawal symptomsDouble-blind clinical trialOpioid-dependent patientsHeroin-dependent patientsPrimary care clinicsWithdrawal symptom scoresSevere withdrawal symptomsDrug treatment programsSubstance abuse treatmentNaltrexone groupCare clinicsSymptom scoresPharmacologic protocolClinical trialsTreatment protocolClonidineTreatment retentionBuprenorphineNaltrexoneTreatment programAbuse treatment